MedTrace Logo

Donepezil Trial for Motor Recovery in Acute Stroke

NCT01442766 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-04-12

No results posted yet for this study

Summary

AIMS: To establish: 1) whether motor deficits in acute stroke improve more in patients taking donepezil, relative to placebo, for 12 weeks; 2) whether brain functional MRI changes as a result of donepezil after 12 weeks.

Conditions

  • Acute Stroke

Interventions

DRUG

Donepezil

5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue

DRUG

Placebo

Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.

Sponsors & Collaborators

  • International Stem Cell Forum

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Paul Bentley, MA MRCP PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-11-30
Completion
2014-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01442766 on ClinicalTrials.gov